Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTT-001
- Development stage
- Preclinical
- Lead developer
- Violet Therapeutics
- Modality
- Small Molecules
01
Overview
VTT-001 (also known as VTX-EphB3 inhibitor) is a small molecule inhibitor of the receptor tyrosine kinase EphB3, currently in preclinical development by Violet Therapeutics. Identified through the company's proprietary C-to-C Engine platform, which maps cell-to-cell communication, VTT-001 is designed to treat neurodegenerative and neuroinflammatory diseases by modulating the interactions between microglia and astrocytes. The drug's mechanism of action involves blocking EphB3-mediated pro-inflammatory signaling, thereby reducing neuroinflammation and promoting synaptic health and cognitive function. Violet Therapeutics is advancing VTT-001 for multiple indications, including Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease, with an Investigational New Drug (IND) application targeted for mid-2026.
- Other names
- unnamed lead compound
02
Targets
EPHB3
Beyond the preview
Go deeper on VTT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTT-001.